Ataciguat

Phase 2Small molecule

Sanofi

Ataciguat is one of 112 small molecule programs targeting Calcification. It is currently in Phase 2.

Indications

Total Trials

Active Trials

111

Competitors

Pipeline

Status by Indication[3][1]

Indication

CalcificationActive, not recruiting

Neuropathic PainActive, not recruiting

Peripheral Arterial DiseaseActive, not recruiting

Aortic Valve StenosisRecruiting

CalcificationPhase 2

Active, not recruiting

Neuropathic PainPhase 2

Active, not recruiting

Peripheral Arterial DiseasePhase 2

Active, not recruiting

Aortic Valve StenosisPreclinical

Recruiting

Competition

Competitive Landscape

212 competitors in Neuropathic Pain

#DrugCompanyPhaseTrials

Elavil

AstraZeneca

Phase 3

4 2

Namenda

AbbVie

Phase 3

3 3

Xylocaine

MMEDRx USA, Inc.

Phase 3

9 4

Briviact

UCB

Phase 3

1 5

Sativex

Jazz Pharmaceuticals

Phase 3

6 6

Ultram

WWim Janssens

Phase 3

2 7

Ketalar

Boehringer Ingelheim

Phase 3

2 8

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

2 9

Aspercreme Warming

AAveritas Pharma, Inc.

Phase 3

1 10

Marcaine

IInnocoll

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

PreclinicalRecruiting

Aortic Valve Stenosis

NCT07001800

Clinical

Trials by Indication[1]

Aortic Valve Stenosis2 trials

Safety of Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis

Completed·—·Phase 1·NCT02049203·44 enrolled

A Phase 2b/3, Randomized, Double-Blinded, Placebo Controlled Study ChecKing the Efficacy and Safety of ATAciguat to Slow the Progression of VaLvular DYsfunction in Participants With Moderate Calcific Aortic Valve STenosis

Recruiting·KKardigan, Inc.·Preclinical·NCT07001800·1,276 enrolled

Calcification1 trial

A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification

Completed·MMayo Clinic·Phase 2·NCT02481258·35 enrolled

Neuropathic Pain1 trial

Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic Pain

Completed· Sanofi logo

Sanofi·Phase 2·NCT00799656·62 enrolled

Peripheral Arterial Disease1 trial

Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease

Completed· Sanofi logo

Sanofi·Phase 2·NCT00443287·553 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Ataciguat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ataciguat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ataciguat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Sanofi

Ataciguat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Aortic Valve Stenosis2 trials

Calcification1 trial

Neuropathic Pain1 trial

Peripheral Arterial Disease1 trial

References

Drug Info

Quick Facts

Related News